Peptides DB
Research-centric peptide and protocol reference hub
Study 4 of 6Navepegritide literatureThe New England journal of medicineTop journal2024

Adjunctive Middle Meningeal Artery Embolization for Subdural Hematoma.

Not reported in abstract.

Read at The New England journal of medicineAdd to compare

Where it sits

this study against the rest of the navepegritide corpus
3
Preclinical · this one
2
Observational
0
Open-label
0
Randomised
1
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2024

Abstract

The authors’ words, as The New England journal of medicine supplied them

<h4>Background</h4>Subacute and chronic subdural hematomas are common and frequently recur after surgical evacuation. The effect of adjunctive middle meningeal artery embolization on the risk of reoperation remains unclear.<h4>Methods</h4>In a prospective, multicenter, interventional, adaptive-design trial, we randomly assigned patients with symptomatic subacute or chronic subdural hematoma with an indication for surgical evacuation to undergo middle meningeal artery embolization plus surgery (treatment group) or surgery alone (control group). The primary end point was hematoma recurrence or progression that led to repeat surgery within 90 days after the index treatment. The clinical secondary end point was deterioration of neurologic function at 90 days, which was assessed with the modified Rankin scale in a noninferiority analysis (margin for risk difference, 15 percentage points).<h4>Results</h4>A total of 197 patients were randomly assigned to the treatment group and 203 to the control group. Surgery occurred before randomization in 136 of 400 patients (34.0%). Hematoma recurrence or progression leading to repeat surgery occurred in 8 patients (4.1%) in the treatment group, as compared with 23 patients (11.3%) in the control group (relative risk, 0.36; 95% confidence interval [CI], 0.11 to 0.80; P = 0.008). Functional deterioration occurred in 11.9% of the patients in the treatment group and in 9.8% of those in the control group (risk difference, 2.1 percentage points; 95% CI, -4.8 to 8.9). Mortality at 90 days was 5.1% in the treatment group and 3.0% in the control group. By 30 days, serious adverse events related to the embolization procedure had occurred in 4 patients (2.0%) in the treatment group, including disabling stroke in 2 patients; no additional events had occurred by 180 days.<h4>Conclusions</h4>Among patients with symptomatic subacute or chronic subdural hematoma with an indication for surgical evacuation, middle meningeal artery embolization plus surgery was associated with a lower risk of hematoma recurrence or progression leading to reoperation than surgery alone. Further study is needed to evaluate the safety of middle meningeal artery embolization in the management of subdural hematoma. (Funded by Medtronic; EMBOLISE ClinicalTrials.gov number, NCT04402632.).

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Navepegritide corpus

CCombination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.Nature medicine · 2016AnimalDUltra-fast deep-learned CNS tumour classification during surgery.Nature · 2023BA Scoping Review of 5-HT&lt;sub&gt;3&lt;/sub&gt; Antagonist Antiemetic Medication Safety in the Management of Nausea and Vomiting of Pregnancy.Pharmacoepidemiology and drug safety · 2024 · Not reported in abstract.reviewBLongitudinal analysis of viral suppression before, during, and after pregnancy among women on antiretroviral therapy in Uganda: six-year real-world experience.HIV research & clinical practice · 2026 · n=1291 · Viral suppression rates before pregnancy were 95.0% for DTG, 94.9% for EFV, 93.1% for NVP, and 79.6% for PI-based therapy.HumanBIntegrating haplotype-enhanced HIV surveillance with national databases improves the resolution of transmission networks, drug resistance, and risk assessment.Emerging microbes & infections · 2023 · n=95 · 91.1% sequence-level network inclusion rate (1452/1594 haplotypes)Human